ClinicalTrials.gg
RecruitingNCT05351112Updated Aug 17, 2025

PMCF Study on the Safety, Performance and Clinical Benefits Data of the Anatomical Shoulder 2.0 Fracture System

An observational study in Proximal Humerus Fracture, Posttraumatic Arthrosis After Humeral Head Fracture and Posttraumatic Necrosis of the Humeral Head, sponsored by Zimmer Biomet. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Zimmer Biomet · Observational

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
78
Ages
18 Years and older
Sex
All
01

Study summary

The study is a multicenter, retrospective and prospective, non-randomized, non-controlled and consecutive series post-market study. The purpose of this study is to collect long-term data confirming safety, performance and clinical benefits of the Anatomical Shoulder 2.0 Fracture System (Implants and Instrumentation) when used for fracture shoulder arthroplasty. The primary objective is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications and adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified.

The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcome measures (PROMs) as well as radiographic outcomes.

Read the detailed description

The Anatomical Shoulder 2.0 Fracture System is intended for use in prosthetic replacement of the proximal humerus and the glenoid articular surface of the scapula during total, hemi and fracture shoulder arthroplasty. The system is intended for long-term implantation into the human shoulder joint to relieve pain and restore function in patients with adequate bone stock to support the prosthesis.

Two sites will be involved in this study. The aim is to include a total of 78 consecutive series cases who received the Anatomical Shoulder 2.0 Fracture starting from 2014. All potential study subjects will be required to participate in the Informed Consent Process.

Baseline data from the preop, intraop and immediate post-op intervals will be available in medical notes and collected retrospectively. During follow-up visits at 1, 3, 5, 7 and 10 years post-op (depending on patients' date of surgery), the patient will be asked to complete patient questionnaires. Moreover, a clinical assessment and a radiographic evaluation will be conducted. In addition, any complications and adverse events will also be collected during these follow-up visits.

02

Conditions studied

  • Proximal Humerus Fracture
  • Posttraumatic Arthrosis After Humeral Head Fracture
  • Posttraumatic Necrosis of the Humeral Head

Keywords

  • Post-Market Clinical Follow-Up Study
  • Medical Device
  • Performance
  • Safety
  • Clinical Benefits
03

In context

Humeral Fractures

106 studies on the registry are indexed under Humeral Fractures; 20 are open to participants now.

This study's planned enrollment of 78 is below the median of 91 across 36 observational studies indexed under Humeral Fractures.

Browse Humeral Fractures studies →

Lead sponsor

Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be comprised of a consecutive series of cases implanted with the Anatomical Shoulder 2.0 Fracture System according to Zimmer Biomet's Instruction for Use (IFU) and who meet the inclusion criteria and none of the exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years or older and skeletally mature
  • Patients capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study
  • Replacement of the proximal humerus and the glenoid articular surface of the scapula during total-, hemi- and fracture shoulder arthroplasty in treatment of the following:

    1. Complex 3- and 4- part fractures of the proximal humerus with subluxation of the head fragment
    2. Complex 3- and 4- part fractures of the proximal humerus with loosening of the spongiosa in the head fragment
    3. Complex 3- and 4- part fractures of the proximal humerus with additional cross split of the head fragment
    4. Fracture instability after osteosynthesis of 3- and 4-part fracture fragments of the proximal humerus
    5. Posttraumatic necrosis of the humeral head
    6. Posttraumatic arthrosis after humeral head fracture

Exclusion criteria

Exclusion Criteria:

  • Patients who are unwilling or unable to give consent, not willing to return for study required follow-up visits and/or to comply with the follow-up program.
  • The patient is known to be pregnant or breastfeeding
  • Patients who have any condition that would in the judgment of the Investigator place the patient at undue risk or interfere with the study.
  • Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant).
  • Patients with plans to relocate during the study follow-up period
  • Signs of infection
  • Extensive stiffening of the shoulder joint without pain
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
78 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients who received the Anatomical Shoulder 2.0 Fracture

    Anatomical Shoulder 2.0 Fracture

06

What researchers measure

Primary outcomes

  1. Incidence and frequency of revisions [Product safety based on implant survivorship]

    Safety will be assessed by recording and analyzing the incidence and frequency of revisions, complications and adverse events. A Kaplan Meier survival curve will be calculated.

    Time frame: 3-10 years

Secondary outcomes

  1. Constant and Murley Score

    The Constant and Murley score is a 100-point functional shoulder assessment tool in which higher scores reflect increased function. The subjective variables are pain (15 points) and function (activities of daily living - sleep, work, recreation/sport; 20 points), for a total of 35 points. The objective variables are active range of motion (clinician assessment; 40 points) and strength (25 points), for a total of 65 points.

    Time frame: 3-10 years

  2. Oxford Shoulder Score

    The OSS is a self-assessment of shoulder pain and function with 12 items; pain (2), interference with pain (2), and daily functions (8). Each response is answered with a five point Likert scale. The total score is the sum of the 12 items, with lower scores indicating a more favorable outcome.

    Time frame: 3-10 years

  3. EuroQol Five Dimensions Questionnaire

    The EQ-5D measures 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with a total of 5 questions. It is accompanied by the patient's self-assessment with the VAS. Each dimension is assigned one of three discrete levels for evaluation on the day of administration: Level 1 - No problems, no disability Level 2 - Some problems, moderate disability Level 3 - A lot of problems, severe disability The final score is a five digit composite of the responses ranging between 33333 - 11111 with 243 possible combinations in between

    Time frame: 3-10 years

  4. X-rays

    Performance and clinical benefits will be assessed by radiographic evaluation. Radiographs (A/P and axillary view) of the operated shoulder will be taken at each interval.

    Time frame: 3-10 years

07

Study locations

1 of 1 sites recruiting
  • Salamenca University Hospital
    Salamanca, 37007, Spain
    Recruiting
    • Alberto Moreno, Dr · Contact
    • Alberto Moreno, Dr · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Jan 2034, 138 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2022
First posted
Apr 28, 2022
StartActual
Jul 7, 2022
Primary completionEst.
Jan 21, 2034
CompletionEst.
Jan 21, 2034
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05351112
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Apr 28, 2022
Start date
Jul 7, 2022
Primary completion
Jan 21, 2034 (estimated)
Completion
Jan 21, 2034 (estimated)
Last update
Aug 17, 2025

Study contacts

Julie Nicoux
Contact
julie.nicoux@zimmerbiomet.com
+33 06 72 61 35 02
Hassan Achakri
study director · Zimmer Biomet

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion